Inhibrx (INBX) Competitors $13.55 +1.24 (+10.07%) Closing price 04:00 PM EasternExtended Trading$13.55 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INBX vs. AVXL, CRON, SEPN, AVDL, RLAY, PRTA, CRMD, SANA, REPL, and QUREShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Anavex Life Sciences (AVXL), Cronos Group (CRON), Septerna (SEPN), Avadel Pharmaceuticals (AVDL), Relay Therapeutics (RLAY), Prothena (PRTA), CorMedix (CRMD), Sana Biotechnology (SANA), Replimune Group (REPL), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Anavex Life Sciences Cronos Group Septerna Avadel Pharmaceuticals Relay Therapeutics Prothena CorMedix Sana Biotechnology Replimune Group uniQure Inhibrx (NASDAQ:INBX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Does the MarketBeat Community favor INBX or AVXL? Anavex Life Sciences received 406 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 74.70% of users gave Anavex Life Sciences an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformInhibrxOutperform Votes3158.49% Underperform Votes2241.51% Anavex Life SciencesOutperform Votes43774.70% Underperform Votes14825.30% Which has stronger valuation & earnings, INBX or AVXL? Anavex Life Sciences has lower revenue, but higher earnings than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx$1.57M125.10-$154.96MN/AN/AAnavex Life SciencesN/AN/A-$43M-$0.52-18.40 Does the media refer more to INBX or AVXL? In the previous week, Anavex Life Sciences had 9 more articles in the media than Inhibrx. MarketBeat recorded 12 mentions for Anavex Life Sciences and 3 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.53 beat Anavex Life Sciences' score of 0.46 indicating that Inhibrx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in INBX or AVXL? 82.5% of Inhibrx shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 22.2% of Inhibrx shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate INBX or AVXL? Anavex Life Sciences has a consensus price target of $44.00, suggesting a potential upside of 359.77%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is INBX or AVXL more profitable? Anavex Life Sciences' return on equity of -33.04% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets InhibrxN/A -113.74% -80.56% Anavex Life Sciences N/A -33.04%-30.19% SummaryAnavex Life Sciences beats Inhibrx on 10 of the 14 factors compared between the two stocks. Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.15M$3.09B$5.62B$9.14BDividend YieldN/A1.87%5.36%3.98%P/E RatioN/A46.7489.6917.66Price / Sales125.10297.571,219.4081.09Price / CashN/A188.8944.3437.71Price / BookN/A4.145.134.73Net Income-$154.96M-$40.99M$118.85M$225.42M7 Day Performance3.51%-0.27%1.87%-0.44%1 Month Performance-10.50%1.57%7.96%3.57%1 Year Performance-65.03%-1.87%26.70%19.20% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx1.5122 of 5 stars$13.55+10.1%N/A-67.6%$196.15M$1.57M0.00166High Trading VolumeAVXLAnavex Life Sciences3.5127 of 5 stars$9.21-9.3%$44.00+377.7%+43.7%$781.19MN/A-17.7140Upcoming EarningsAnalyst ForecastCRONCronos Group1.5298 of 5 stars$1.99+1.0%$3.00+50.8%-8.7%$760.78M$87.24M-15.31450Short Interest ↓SEPNSepternaN/A$16.89-0.5%$43.67+158.5%N/A$749.92MN/A0.00N/ANews CoverageAVDLAvadel Pharmaceuticals3.1477 of 5 stars$7.75-3.1%$21.00+171.0%-47.5%$746.79M$27.96M-9.8170Positive NewsRLAYRelay Therapeutics2.2429 of 5 stars$4.46+3.2%$20.50+359.6%-54.9%$746.52M$25.55M-1.71330Insider TradeShort Interest ↑High Trading VolumePRTAProthena2.1983 of 5 stars$13.77+4.5%$46.50+237.7%-53.2%$740.96M$91.37M-5.55130Analyst RevisionNews CoveragePositive NewsCRMDCorMedix2.5623 of 5 stars$12.17-4.8%$15.67+28.7%+237.0%$738.48M$60,000.00-15.0230Gap DownSANASana Biotechnology3.0683 of 5 stars$3.16-2.8%$14.25+350.9%-45.7%$705.53MN/A-2.26380Short Interest ↑REPLReplimune Group4.3208 of 5 stars$10.14-2.1%$17.29+70.5%+73.5%$693.78MN/A-3.32210Upcoming EarningsQUREuniQure3.5299 of 5 stars$14.05-1.1%$33.88+141.1%+154.4%$684.84M$28.59M-2.83500Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Anavex Life Sciences Alternatives Cronos Group Alternatives Septerna Alternatives Avadel Pharmaceuticals Alternatives Relay Therapeutics Alternatives Prothena Alternatives CorMedix Alternatives Sana Biotechnology Alternatives Replimune Group Alternatives uniQure Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INBX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
